glp-1 bmi Efficacy of on weight loss, BMI, and waist circumference for adults with overweight or obesity Who Qualifies for Semaglutide GLP-1

weight loss), coexisting medical diseases, and last but not least, the opinion of the patient

Persons with type 2 diabetes tend to also have some degree of increased body weight or obesity and we know that achieving at least 5% body weight helps to improve glucose and cardiometabolic risk factors. MNT spoke with Jennifer Cheng, DO, chief of endocrinology at Hackensack Meridian Jersey Shore University Medical Center in New Jersey who was not involved in this study who commented it is important to find new options for the treatment of type 2 diabetes and give patients the choice of administering either via subcutaneous injections or just a daily pill

A comprehensive medical history is essential to identify contraindications, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, as GLP-1 agonists carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies

Broadening use beyond diabetes in tackling comorbidities Perhaps most transformative is that GLP-1 therapies are no longer confined to diabetes alone

Moreover, while effective for some, biologics often fail to achieve sustained disease control and are associated with significant costs, potential side effects, and limited accessibility in some regions [6]

Novo Nordisks Response to JAMA Study and Allegations In an emailed statement, Wegovy manufacturer Novo Nordisk countered that there were several limitations of the JAMA study design, which was not a randomized controlled trial, as reported by Reuters